Texas 2015 84th Regular

Texas Senate Bill SB332 House Committee Report / Bill

Filed 02/02/2025

Download
.pdf .doc .html
                    By: Schwertner, et al. S.B. No. 332
 (Hunter)


 A BILL TO BE ENTITLED
 AN ACT
 relating to the use of maximum allowable cost lists related to
 pharmacy benefits.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  Chapter 1369, Insurance Code, is amended by
 adding Subchapter H to read as follows:
 SUBCHAPTER H. MAXIMUM ALLOWABLE COST
 Sec. 1369.351.  DEFINITIONS. In this subchapter:
 (1)  "Health benefit plan" has the meaning assigned by
 Section 1369.251, as added by Chapter 915 (H.B. 1358), Acts of the
 83rd Legislature, Regular Session, 2013.
 (2)  "Pharmacy benefit manager" has the meaning
 assigned by Section 4151.151.
 Sec. 1369.352. CERTAIN BENEFITS EXCLUDED.  This subchapter
 does not apply to maximum allowable costs for pharmacy benefits
 provided under:
 (1)  a Medicaid managed care program operated under
 Chapter 533, Government Code;
 (2)  a Medicaid program operated under Chapter 32,
 Human Resources Code;
 (3)  the child health plan program under Chapter 62,
 Health and Safety Code;
 (4)  the health benefits plan for children under
 Chapter 63, Health and Safety Code;
 (5)  a health benefit plan issued under Chapter 1551,
 1575, 1579, or 1601; or
 (6)  a workers' compensation insurance policy or other
 form of providing medical benefits under Title 5, Labor Code.
 Sec. 1369.353.  CRITERIA FOR DRUGS ON MAXIMUM ALLOWABLE COST
 LISTS. A health benefit plan issuer or pharmacy benefit manager may
 not include a drug on a maximum allowable cost list unless:
 (1)  the drug:
 (A)  has an "A" or "B" rating in the most recent
 version of the United States Food and Drug Administration's
 Approved Drug Products with Therapeutic Equivalence Evaluations,
 also known as the Orange Book; or
 (B)  is rated "NR" or "NA" or has a similar rating
 by a nationally recognized reference; and
 (2)  the drug is:
 (A)  generally available for purchase by
 pharmacists and pharmacies in this state from a national or
 regional wholesaler; and
 (B)  not obsolete.
 Sec. 1369.354.  FORMULATION OF MAXIMUM ALLOWABLE COSTS;
 DISCLOSURES. (a)  In formulating the maximum allowable cost price
 for a drug, a health benefit plan issuer or pharmacy benefit manager
 may only use the price of that drug and any drug listed as
 therapeutically equivalent to that drug in the most recent version
 of the United States Food and Drug Administration's Approved Drug
 Products with Therapeutic Equivalence Evaluations, also known as
 the Orange Book.
 (b)  Notwithstanding Subsection (a), if a therapeutically
 equivalent generic drug is unavailable or has limited market
 presence, a health benefit plan issuer or pharmacy benefit manager
 may place on a maximum allowable cost list a drug that has:
 (1)  a "B" rating in the most recent version of the
 United States Food and Drug Administration's Approved Drug Products
 with Therapeutic Equivalence Evaluations, also known as the Orange
 Book; or
 (2)  an "NR" or "NA" rating or a similar rating by a
 nationally recognized reference.
 (c)  A health benefit plan issuer or pharmacy benefit manager
 must, in accordance with Subsection (d), disclose to a pharmacist
 or pharmacy the sources of the pricing data used in formulating
 maximum allowable cost prices.
 (d)  The information described by Subsection (c) must be
 disclosed:
 (1)  on the date the health benefit plan issuer or
 pharmacy benefit manager enters into the contract with the
 pharmacist or pharmacy; and
 (2)  after that contract date, on the request of the
 pharmacist or pharmacy.
 Sec. 1369.355.  UPDATES. (a)  A health benefit plan issuer
 or pharmacy benefit manager shall establish a process that will in a
 timely manner eliminate drugs from maximum allowable cost lists or
 modify maximum allowable cost prices to remain consistent with
 changes in pricing data used in formulating maximum allowable cost
 prices and product availability.
 (b)  A health benefit plan issuer or pharmacy benefit manager
 shall review and update maximum allowable cost price information
 for each drug at least once every seven days to reflect any
 modification of maximum allowable cost pricing.
 Sec. 1369.356.  ACCESS TO MAXIMUM ALLOWABLE COST LISTS. A
 health benefit plan issuer or pharmacy benefit manager must provide
 to each pharmacist or pharmacy under contract with the health
 benefit plan issuer or pharmacy benefit manager a process to
 readily access the maximum allowable cost list that applies to the
 pharmacist or pharmacy.
 Sec. 1369.357.  APPEAL FROM MAXIMUM ALLOWABLE COST PRICE
 DETERMINATION. (a)  A health benefit plan issuer or pharmacy
 benefit manager must provide in the contract with each pharmacist
 or pharmacy a procedure for the pharmacist or pharmacy to appeal a
 maximum allowable cost price of a drug on or before the 10th day
 after the date a pharmacy benefit claim for the drug is made.
 (b)  The health benefit plan issuer or pharmacy benefit
 manager shall respond to an appeal described by Subsection (a) in a
 documented communication not later than the 10th day after the date
 the appeal is received by the health benefit plan issuer or pharmacy
 benefit manager.
 (c)  If the appeal is successful, the health benefit plan
 issuer or pharmacy benefit manager shall:
 (1)  adjust the maximum allowable cost price that is
 the subject of the appeal effective on the day after the date the
 appeal is decided;
 (2)  apply the adjusted maximum allowable cost price to
 all similarly situated pharmacists and pharmacies as determined by
 the health benefit plan issuer or pharmacy benefit manager; and
 (3)  allow the pharmacist or pharmacy that succeeded in
 the appeal to reverse and rebill the pharmacy benefit claim giving
 rise to the appeal.
 (d)  If the appeal is not successful, the health benefit plan
 issuer or pharmacy benefit manager shall disclose to the pharmacist
 or pharmacy:
 (1)  each reason the appeal is denied; and
 (2)  the national drug code number from the national or
 regional wholesalers from which the drug is generally available for
 purchase by pharmacists and pharmacies in this state at the maximum
 allowable cost price that is the subject of the appeal.
 Sec. 1369.358.  CONFIDENTIALITY OF MAXIMUM ALLOWABLE COST
 LIST. A maximum allowable cost list that applies to a pharmacist or
 pharmacy and is maintained by a health benefit plan issuer or
 pharmacy benefit manager is confidential.  This section may not be
 construed to alter a health benefit plan issuer's or pharmacy
 benefit manager's obligations under Section 1369.356.
 Sec. 1369.359.  WAIVER PROHIBITED. The provisions of this
 subchapter may not be waived, voided, or nullified by contract.
 Sec. 1369.360.  REMEDIES NOT EXCLUSIVE. This subchapter may
 not be construed to waive a remedy at law available to a pharmacist
 or pharmacy.
 Sec. 1369.361.  ENFORCEMENT. The commissioner shall enforce
 this subchapter.
 Sec. 1369.362.  LEGISLATIVE DECLARATION. It is the intent
 of the legislature that, except with respect to the benefits
 excluded under Section 1369.352, the requirements contained in this
 subchapter apply to all health benefit plan issuers and pharmacy
 benefit managers unless otherwise prohibited by federal law.
 SECTION 2.  This Act applies only to a contract between a
 health benefit plan issuer or a pharmacy benefit manager and a
 pharmacist or pharmacy entered into or renewed on or after January
 1, 2016. A contract entered into or renewed before January 1, 2016,
 is governed by the law as it existed immediately before the
 effective date of this Act, and that law is continued in effect for
 that purpose.
 SECTION 3.  This Act takes effect January 1, 2016.